West Pharmaceutical Services Issues Statement on Exubera

LIONVILLE, Pa., Oct. 18 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST ) today provided comments related to Pfizer, Inc.'s announcement that it has decided to discontinue marketing the Exubera Inhalable Insulin product, returning the marketing rights to the Company's ...

New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer

...

Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results

...56,321 61,832 207,254 Operating costs and expenses: Cost of goods sold 5,349 27,457 18,020 123,469 Cost of idle exubera manufacturing capacity 6,821 Research and development 38,265 35,773 109,138 114,265 General...

West Announces Third Quarter 2008 Results

...or certain anemia, or ESA, drugs, the discontinued exubera inhalable insulin device, and certain disposable m...r-margin products, particularly ESA components and exubera devices, and to raw material and other production ... Company's costs of maintaining and converting the exubera device production facility and related tangible in...

Nektar Therapeutics Announces Second Quarter 2008 Results

...margin associated with Pfizer's termination of the exubera collaboration and maintenance of exubera manufacturing capacity through April 2008. The fin...and charges associated with the termination of the exubera inhaled insulin program were paid and recorded in ...

West Announces Second Quarter 2008 Results

...to the manufacture of devices for the discontinued exubera product, net of $1.4 million of restructuring cost...ear period. Lower sales were due to the absence of exubera inhalable insulin device sales and of packaging fo...the Company's costs of maintaining and closing the exubera device production facility and of related tangible...

Nektar Therapeutics Announces First Quarter 2008 Results

...he first quarter of 2007. This decrease is the result of the termination of exubera by Pfizer. "The first quarter was significant for Nektar as it represents...ds sold 7,227 56,522 Cost of idle exubera manufacturing capacity 5,334 ...

Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results

... 38,489 12,053 85,925 56,303 exubera commercialization readiness ...87 40,100 137,696 113,921 Cost of idle exubera manufacturing capacity 6,314 - 6,314 - exubera commercialization readiness costs ...

Endocrinology Panel Examines Interplay Between Diabetes and Cardiovascular Disease in New Report

...ow each fits into the diabetes / CAD paradigm. -- The Panel describes why exubera has failed commercially, and benchmarks next-generation insulins. -- ...Nordisk), Actos (pioglitazone; Takeda/Lilly), Avandia (rosiglitazone; GSK), exubera (Nektar), AIR Insulin (Lilly/Alkermes), Technosphere (Mannkind), AERx (Novo...

MannKind Corporation Reports Third Quarter Financial Results

...y received $250 million in gross proceeds from its self managed registered direct offering of approximately 27 million shares of common stock. "While exubera stumbled in the marketplace and then was ultimately withdrawn, our Technosphere Insulin is very different and continues to be well received by patient...

Exubera in Medical Technology

MannKind Addresses Pfizer's Announcement Regarding Exubera

VALENCIA, Calif., April 10 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD ) released the following statement in response to the announcement by Pfizer Inc. that over the course of Exubera's clinical trial program, 6 of the 4,740 patients treated with Exubera developed lung cance...

Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients

..." Nektar will cease all spending associated with its inhaled insulin programs and will not incur any additional charges related to this event. The exubera label was updated by Pfizer to contain the following safety information warning: "In clinical trials of Exubera, there have been 6 newly diagnosed c...

Exubera in Biological Technology

MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility

...of diabetes on a commercial scale. This has been a busy week for MannKind. Yesterday, we announced a collaboration with Pfizer that will allow certain exubera patients with an urgent medical need for inhaled insulin to transition to AFRESA on a compassionate use basis. In addition, we released some top-line ...